Faricimab vs aflibercept in patients with DME: Jennifer Lim, ARVO 2023 скачать в хорошем качестве

Faricimab vs aflibercept in patients with DME: Jennifer Lim, ARVO 2023

Faricimab inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways which may extend treatment durability beyond current anti-VEGF therapies for diabetic macular edema (DME). It was a pleasure to speak with Dr Jennifer Lim (University of Illinois Chicago, IL, USA) around the treat-and-extend regimen with faricimab in the YOSEMITE/RHINE (NCT03622580/NCT03622593) trials and the long-term potential of faricimab to reduce treatment burden for patients with DME. The presentation entitled ‘Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME’ was presented at the Association for Research in Vision and Ophthalmology Annual Meeting, May 05-09, 2023 Questions: What is the rationale for using faricimab in the treatment of DME? (0:22) What were the primary and secondary endpoints and how well were they achieved? (1:09) What will be the likely clinical impact of these findings? (2:42) Disclosures: Jennifer Lim is a consultant for Genentech, Regeneron, Opthea, Cognition, Viridian, Santen, Quark, Luxa, Aura, Alimera, Unity & Eyenuk and discloses grant/research support from Genentech, Regeneron, Aldeyra, NGM, , Adverum, Regenexbio, Janssen & Spring Vision. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen. Filmed in coverage of the virtual ARVO 2023.